INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXPRNewsWire · 2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXGlobeNewsWire · 4 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXPRNewsWire · Oct 15, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTXGlobeNewsWire · Oct 13, 2026
FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS LawGuruFocus · Oct 11, 2026
FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS LawBusiness Wire · Oct 11, 2026Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.25 | -$0.10 | Beat |
| May 7, 2026 | -$0.28 | -$0.29 | Miss |
| Mar 11, 2026 | -$0.28 | -$0.34 | Miss |
| Nov 5, 2025 | -$0.31 | -$0.25 | Beat |
| Aug 5, 2025 | -$0.31 | -$0.28 | Beat |
| May 14, 2025 | -$0.30 | -$0.30 | Beat |